Q2 2023

Filed Aug 8, 2023 · 10-Q · 39 days after period end · 0001787306-23-000077

Q2 2023 · 10-Q

Revenue

$5.19M

— vs Q2 2022

Net Income

-$70.99M

N/M vs Q2 2022

EPS Diluted

-$1.16

N/M vs Q2 2022

Operating Income-$66,763,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	$5.19M	$0.00	—	—
Net Income	-$70.99M	-$67.41M	-$42.01M	-$35.41M
EPS Diluted	-$1.16	-$1.31	-$0.84	-$0.94

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR